ThiamEt-G is orally available and increases brain O-GlcNAc levels in mammals and has been used by several groups to show chronic OGA inhibition and increased O-GlcNAcylation over several months has no apparent deleterious effects and also protects in various mouse models of AD against both tau14,37,38 and amyloid pathologies.39,40 Given the great interest in OGA inhibitors as research tools, we aimed to explore the basis for the inhibition of hOGA by ThiamEt-G. The gene discussed is OGA; the disease is Alzheimer disease.